Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.
OBJECTIVE
To report a possible interaction between foscarnet and ciprofloxacin in two patients with AIDS, cytomegalovirus (CMV) retinitis, and disseminated Mycobacterium avium complex (MAC) infection and to review the available literature related to foscarnet-associated seizures.


METHODS
Case report information was obtained from Medical Service Daily Rounds during the patients' hospitalization and from the patients' medical records. Computerized (MEDLINE) and manual (Index Medicus) search methods were used to obtain English-language literature published between 1980 and 1993.


RESULTS
Foscarnet is a synthetic antiviral agent with activity against herpesviruses and HIV. The incidence of seizures with foscarnet infusion is high, ranging from 13 to 15 percent. Predisposing factors such as renal impairment, electrolyte and metabolic abnormalities, and underlying neurologic disorders have been associated with seizures during foscarnet therapy. We describe two patients with AIDS who developed generalized tonic-clonic seizures while receiving foscarnet and ciprofloxacin for the treatment of CMV retinitis and disseminated MAC infection, respectively. Neither of the patients had any of the aforementioned risk factors for foscarnet-associated seizures.


CONCLUSIONS
Concurrent administration of ciprofloxacin, a known epileptogenic agent, and foscarnet may predispose patients to the development of seizures.
Fan-Harvard
P
P
Rutgers College of Pharmacy, Piscataway, NJ.
Sanchorawala
V
V
Oh
J
J
Moser
E M
EM
Smith
S P
SP
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000328:Adult; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy; D004347:Drug Interactions; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced*; D017245:Foscarnet / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy
D017245:Foscarnet; D002939:Ciprofloxacin